JP7398677B2 - ウテログロビンを構造基盤とする二重特異性ポリペプチド - Google Patents

ウテログロビンを構造基盤とする二重特異性ポリペプチド Download PDF

Info

Publication number
JP7398677B2
JP7398677B2 JP2020506514A JP2020506514A JP7398677B2 JP 7398677 B2 JP7398677 B2 JP 7398677B2 JP 2020506514 A JP2020506514 A JP 2020506514A JP 2020506514 A JP2020506514 A JP 2020506514A JP 7398677 B2 JP7398677 B2 JP 7398677B2
Authority
JP
Japan
Prior art keywords
uteroglobin
chain
polypeptide
heterodimeric
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020506514A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019176866A1 (ja
JPWO2019176866A5 (https=
Inventor
真由美 新山
宏樹 秋葉
康弘 阿部
諭志 永田
知子 伊勢
知生子 長尾
春彦 鎌田
浩平 津本
賢司 水口
アリーナ・アファナシェヴァ
豪 井上
庸太 福田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Biomedical Innovation Health and Nutrition
University of Osaka NUC
Original Assignee
Osaka University NUC
National Institutes of Biomedical Innovation Health and Nutrition
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, National Institutes of Biomedical Innovation Health and Nutrition filed Critical Osaka University NUC
Publication of JPWO2019176866A1 publication Critical patent/JPWO2019176866A1/ja
Publication of JPWO2019176866A5 publication Critical patent/JPWO2019176866A5/ja
Application granted granted Critical
Publication of JP7398677B2 publication Critical patent/JP7398677B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020506514A 2018-03-12 2019-03-11 ウテログロビンを構造基盤とする二重特異性ポリペプチド Active JP7398677B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018044364 2018-03-12
JP2018044364 2018-03-12
PCT/JP2019/009745 WO2019176866A1 (ja) 2018-03-12 2019-03-11 ウテログロビンを構造基盤とする二重特異性ポリペプチド

Publications (3)

Publication Number Publication Date
JPWO2019176866A1 JPWO2019176866A1 (ja) 2021-02-25
JPWO2019176866A5 JPWO2019176866A5 (https=) 2022-03-16
JP7398677B2 true JP7398677B2 (ja) 2023-12-15

Family

ID=67907143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020506514A Active JP7398677B2 (ja) 2018-03-12 2019-03-11 ウテログロビンを構造基盤とする二重特異性ポリペプチド

Country Status (2)

Country Link
JP (1) JP7398677B2 (https=)
WO (1) WO2019176866A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137160A1 (en) * 2023-12-18 2025-06-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Cc16-derived analogs for the treatment of inflammatory and obstructive lung diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521316A (ja) 1998-07-21 2002-07-16 クララジェン、インコーポレイテッド 炎症および線維症症状の治療における組換えヒトウテログロビンの使用
US20130189735A1 (en) 2009-01-19 2013-07-25 Luciano Zardi Process for engineering polyvalent, polyspecific fusion proteins using uteroglobin as skeleton and so obtained products.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521316A (ja) 1998-07-21 2002-07-16 クララジェン、インコーポレイテッド 炎症および線維症症状の治療における組換えヒトウテログロビンの使用
US20130189735A1 (en) 2009-01-19 2013-07-25 Luciano Zardi Process for engineering polyvalent, polyspecific fusion proteins using uteroglobin as skeleton and so obtained products.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MUKHERJEE, AB et al.，Uteroglobin: a novel cytokine?，Cellular and Molecular Life Sciences，1999年，Vol. 55，pp. 771-787
SPIESS, C et al.，Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies，Nature Biotechnology，2013年，Vol. 31, No. 8，pp. 753-758
VENTURA, E et al.，Use of the Uteroglobin Platform for the Expression of a Bivalent Antibody against Oncofetal Fibronectin in Escherichia coli，PLOS ONE，2013年，Vol. 8, No. 12，e82878
浅野竜太郎ほか，タンパク質工学を駆使した高機能性二重特異性抗体の開発，生化学，2014年，第86巻第4号，pp. 469-473

Also Published As

Publication number Publication date
WO2019176866A1 (ja) 2019-09-19
JPWO2019176866A1 (ja) 2021-02-25

Similar Documents

Publication Publication Date Title
JP6449359B2 (ja) 免疫原性の低いｔ細胞及び／又はｂ細胞エピトープを有するシュードモナス外毒素ａ
TWI840433B (zh) 新穎合理設計的蛋白質組合物
KR102709815B1 (ko) 인간 cd3 결합 항체
EP2755993B1 (en) Pseudomonas exotoxin a with less immunogenic b cell epitopes
EP2527370A1 (en) Compounds having resistance to soluble CEA
AU2012268013A1 (en) Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
CN113527487A (zh) 抗人b7-h3的单克隆抗体及其应用
CN110835374A (zh) 抗ccr8×ctla-4双特异性抗体及其应用
WO2023046156A1 (en) Il-2 variants and fusion proteins thereof
TWI825459B (zh) 一種SIRPα-Fc融合蛋白
Schaedel et al. Antibodies and their fragments as anti-cancer agents
US12215164B2 (en) Immunotoxins with albumin binding domain
WO2018036117A1 (zh) 靶向于组织因子的抗体、其制备方法和用途
JP7398677B2 (ja) ウテログロビンを構造基盤とする二重特異性ポリペプチド
WO2024199458A1 (en) Il-2 variants with improved stability and compositions thereof
HK1192572A (en) Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231122

R150 Certificate of patent or registration of utility model

Ref document number: 7398677

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150